7000 Shoreline Court, Suite 320
South San Francisco, CA 94080
Telephone: (415) 645-6537
Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with, or caused by, latent or persistent viral reservoirs.
Agenovir’s mission is to develop innovative treatments that disrupt or eliminate pathogenic viral genomes, bringing hope to patients who suffer from devastating, persistent viral infection.